**Problem:** Lack of new targets with human validation **Tenaya Solution:** Expand pipeline by using human iPSC-derived CM disease models and analysis of human genetics to identify new targets and therapies [[Tenaya Deep Dive]] Precision Medicine platform uses human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) as proprietary disease models and analysis of human genetics for the identification of new targets, validation of known targets, and high-throughput screening for drug discovery. This platform is intended to overcome the shortcomings of traditional drug development efforts that rely more heavily on efficacy in animal models to develop therapies intended for human heart disease. We believe this platform has potentially broad utility for the identification of targets and therapies in a modality-agnostic manner—including gene therapy, small molecules, and biologics—for both genetic and non-genetic forms of heart disease.